Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer

[1]  K. Alitalo,et al.  SnapShot: Angiopoietins and Their Functions , 2017, Cell.

[2]  Prahlad T. Ram,et al.  Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression , 2017, Clinical Cancer Research.

[3]  K. Baggerly,et al.  Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy , 2017, Oncotarget.

[4]  Doheon Lee,et al.  Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. , 2016, Cancer cell.

[5]  Gordon C Jayson,et al.  Antiangiogenic therapy in oncology: current status and future directions , 2016, The Lancet.

[6]  G. Jayson,et al.  Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab , 2016, British Journal of Cancer.

[7]  D. Cunningham,et al.  Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial , 2015, The Lancet. Oncology.

[8]  Brian Neelon,et al.  Evaluation of treatment efficacy using a Bayesian mixture piecewise linear model of longitudinal biomarkers , 2015, Statistics in medicine.

[9]  S. Luo,et al.  Bayesian hierarchical model for multiple repeated measures and survival data: an application to Parkinson's disease , 2014, Statistics in medicine.

[10]  I. Keklikoglou,et al.  Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. , 2014, Cell reports.

[11]  Q. Yu,et al.  Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment. , 2014, The American journal of pathology.

[12]  B. Monk,et al.  Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Oncology.

[13]  A. Oza,et al.  The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer , 2014, Clinical Cancer Research.

[14]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Hoff,et al.  Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy , 2013, British Journal of Cancer.

[16]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[17]  Barbara Sennino,et al.  Controlling escape from angiogenesis inhibitors , 2012, Nature Reviews Cancer.

[18]  M. Ranson,et al.  Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer , 2012, British Journal of Cancer.

[19]  Verena D. Schmittmann,et al.  Qgraph: Network visualizations of relationships in psychometric data , 2012 .

[20]  Douglas G. Altman,et al.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration , 2012, PLoS medicine.

[21]  A. Jackson,et al.  Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies , 2012, Nature Reviews Clinical Oncology.

[22]  B. Karlan,et al.  Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[24]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[25]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[27]  John K Kruschke,et al.  Bayesian data analysis. , 2010, Wiley interdisciplinary reviews. Cognitive science.

[28]  Thomas Benner,et al.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Geoff J M Parker,et al.  Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging , 2009, Clinical Cancer Research.

[30]  Caroline Dive,et al.  Tumorigenesis and Neoplastic Progression Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy , 2010 .

[31]  R. Herbst,et al.  Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Jayson,et al.  'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. , 2009, Journal of immunological methods.

[33]  E. D. de Vries,et al.  Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. , 2008, Neoplasia.

[34]  A. Jackson,et al.  Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. , 2008, The Lancet. Oncology.

[35]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Naldini,et al.  Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. , 2007, Cancer research.

[37]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[38]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Jackson,et al.  Experimentally‐derived functional form for a population‐averaged high‐temporal‐resolution arterial input function for dynamic contrast‐enhanced MRI , 2006, Magnetic resonance in medicine.

[40]  G. Jayson,et al.  Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP , 2006, British Journal of Cancer.

[41]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[42]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[43]  N. Yang,et al.  Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. , 2003, Cancer research.

[44]  J L Evelhoch,et al.  Key factors in the acquisition of contrast kinetic data for oncology , 1999, Journal of magnetic resonance imaging : JMRI.

[45]  W. Barlow,et al.  Residuals for relative risk regression , 1988 .

[46]  Robert Tibshirani,et al.  Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy , 1986 .

[47]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[48]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[49]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[50]  P. Tofts.  Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[51]  D. Cox.  Regression Models and Life-Tables , 1972 .